Rodon Biologics, a leading biotech CRO/CDMO, has 20 years delivering protein solutions tailored for discovery research and beyond. The company specializes in engineering, producing, analyzing, and characterizing recombinant proteins, as well as small molecules derived from engineered microorganisms.

Rodon delivers comprehensive solutions—including processes, data, and products—tailored for discovery, early-stage research, preclinical development, and manufacturing. Established in 1999 as Biotecnol, the company initially focused on supporting the development of recombinant protein therapeutics and has since expanded its expertise and service offerings, specializing in cell-culture based development and production of proteins and other molecule types using engineered E.coli, Yeast, and Mammalian cells.